Lipid nanoparticles

Lipid nanoparticles are small synthetic vesicles, typically 60 to 100 nanometres across, that package fragile nucleic acids and ferry them across a cell membrane. They are the reason mRNA vaccines work, the reason the first systemically delivered CRISPR therapy reached patients, and — because they deposit their cargo overwhelmingly in the liver — the reason most in vivo genome-editing programmes as of 2026 target a hepatic gene. Unlike AAV vectors, they carry no viral protein, provoke no lasting anti-vector immunity, and can be given more than once.

§How it works

The active ingredient is the ionizable lipid. It carries an amine that is uncharged at blood pH, so the circulating particle is close to neutral and avoids the toxicity and rapid clearance that plagued the permanently cationic lipids of the 1990s. Inside the acidifying endosome, the amine picks up a proton. The now-positive lipid pairs with anionic endosomal phospholipids, destabilises the membrane, and lets a fraction of the RNA escape into the cytosol before the compartment matures into a lysosome and degrades the rest.

The other three components are structural. A helper phospholipid, usually DSPC, and cholesterol set the particle's phase behaviour and rigidity; a polyethylene-glycol-conjugated lipid coats the surface, controls particle size during mixing, and slows opsonisation. The particles are made by rapid microfluidic mixing of a lipid-in-ethanol stream with an acidic aqueous stream containing the RNA, which drives self-assembly in milliseconds.

Endosomal escape remains startlingly inefficient. Only a small percentage of internalised cargo reaches the cytosol; the rest is destroyed or recycled out. Most of the potency gains over fifteen years have come from screening thousands of ionizable-lipid structures rather than from any single conceptual advance, and the field still lacks a predictive theory of what makes one escape better than another. Self-assembling lipid vesicles are, in this sense, a cruder object than the addressable structures of DNA nanotechnology — and vastly more successful in the clinic.

§Development history

Liposomal drug delivery dates to the 1960s, but the specific lineage behind modern particles runs through Pieter Cullis's laboratory in Vancouver and the companies that spun out of it. The key move, made in the late 2000s, was replacing permanently charged cationic lipids with ionizable ones whose pKa could be tuned; systematic structure-activity work identified formulations that delivered siRNA to hepatocytes at doses two orders of magnitude lower than earlier designs.¹

That work produced patisiran, approved in 2018 as the first siRNA therapeutic and the first licensed nucleic-acid LNP drug. It also produced the delivery platform that the COVID-19 mRNA vaccines used two years later, at a scale — billions of doses — that settled questions about manufacturability and short-term safety no clinical trial programme could have settled alone.

What the vaccines proved

Before 2020 the honest description of LNPs was a promising delivery technology with one approved product. Mass vaccination demonstrated tolerable reactogenicity across all ages, workable cold-chain logistics, and industrial-scale production. That evidence base is what made regulators willing to consider systemic in vivo genome editing a few years later.

§Liver tropism and how to escape it

Injected intravenously, a conventional LNP adsorbs apolipoprotein E from plasma. ApoE is a ligand for the low-density lipoprotein receptor, which hepatocytes display abundantly, and the particle is taken up as though it were a lipoprotein.² The liver's fenestrated endothelium does the rest. This is convenient if the target gene is expressed in the liver and a hard obstacle otherwise.

Two approaches redirect the particles elsewhere. The first alters the formulation itself: adding a fifth charged lipid shifts the protein corona that forms in blood and, with it, the destination organ, sending particles preferentially to lung or spleen.³ The second attaches a targeting ligand — an antibody or peptide against a surface marker — to the PEG-lipid. Antibody-targeted particles have been used in animals to make chimeric antigen receptor T cells inside the body rather than in a manufacturing facility,⁴ and to reach haematopoietic stem cells in the marrow, which if it translated would remove the chemotherapy conditioning that limits Casgevy and similar products.

Neither approach has yet produced an approved extrahepatic product. Local administration sidesteps the problem where anatomy allows: inhaled particles for airway disease, intramuscular injection for vaccines, intratumoural injection in oncology.

§In vivo genome editing

Transient expression is a liability for gene replacement and a virtue for editing. An editor needs to act once and then disappear; anything that lingers accumulates off-target edits without adding benefit. mRNA delivered by LNP is translated for a day or two and cleared, which is close to the ideal exposure profile. The carrier and its cargo are gone within days; the edit they make is not. Size is no obstacle either: an mRNA encoding a Prime editing complex, far too large for a single viral capsid, packages into an LNP without difficulty.

The proof came with NTLA-2001, which delivers Cas9 mRNA and a guide targeting the transthyretin gene in hepatocytes. Interim results published in 2021 showed dose-dependent, durable falls in circulating transthyretin after a single infusion, with a mean reduction of roughly 87 percent at the higher dose tested.⁵ It was the first demonstration that CRISPR–Cas9 could be administered systemically to a human being and knock out a gene in a solid organ. A companion programme knocking out prekallikrein for hereditary angioedema followed, and cardiovascular programmes using Base editing to disable PCSK9 have reported sustained reductions in LDL cholesterol after a single dose.

The most striking application to date treated one patient. In 2025 a team at the University of Pennsylvania and the Children's Hospital of Philadelphia designed, manufactured, and administered a base-editing therapy for an infant with a severe urea-cycle disorder, moving from the identification of his specific mutation to first dose in about six months.⁶ The therapy exists for a single person and cannot be commercialised in any conventional sense, which makes it an unsolved problem for regulators and payers as much as a technical achievement. It is also the clearest illustration of a general point: platform delivery plus programmable editing means the bottleneck for ultra-rare disease is no longer biology, and the arguments in Access and inequality apply with unusual force.

§Limitations and risks

Reactogenicity is dose-limiting for systemic use. Infusion reactions, complement activation, and transient inflammatory responses are attributable partly to the ionizable lipid and partly to innate sensing of the RNA cargo; premedication is standard in therapeutic dosing. Antibodies against polyethylene glycol, which many people carry from consumer products, can accelerate clearance of repeat doses and contribute to hypersensitivity.

The transience that suits editing rules LNPs out for gene replacement, where continuous expression of a missing protein is the point. They also do not cross the blood-brain barrier, leaving neurological targets to AAV, intrathecal antisense oligonucleotides, or nothing. Manufacturing requires cold storage and lipid supply chains that remain concentrated among a small number of producers.

A subtler concern is how easy the platform makes things. A delivery system that is programmable by sequence, redosable, and cheap to iterate lowers the barrier for both legitimate therapy and misuse; the same properties feature in discussions of Dual-use research of concern and in the oversight questions raised in Governance of human genome editing.

§Outlook

The near-term trajectory is more editing programmes in the liver, where the technology already works, and a slow attack on everything else. If antibody-targeted particles reach blood stem cells in humans at useful efficiency, the consequences would be larger than any single therapy: inherited blood disease could be treated by injection rather than transplantation. Extending the same logic to muscle, brain, or the immune system would broaden genetic medicine well beyond the few hundred conditions currently in reach, and would be relevant to speculative programmes such as Gene therapy for aging that require repeated dosing across many tissues. Whether that happens depends on a problem the field has not solved in twenty years of effort — getting a nanoparticle to a chosen cell type without the liver taking it first, the same obstacle that has defeated most claims made for Targeted drug delivery and for Medical nanorobots.

§See also

• AAV vectors
• CRISPR–Cas9
• Base editing
• Casgevy
• Somatic gene therapy
• Targeted drug delivery
• DNA nanotechnology
• Human germline editing

§References